For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the introduction of Tafamidis and Attruby represents a genuine change. These innovative therapies protect the transthyretin protein, preventing its damaging build-up and alleviating the burden of the condition . Individuals are now experiencing improveme